GondolaBio · 2 months ago
Vice President Oligonucleotide Therapeutics
Palo Alto, CA
Full-time
Onsite
Director/Executive
$290K/yr - $340K/yr
12+ years expGondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. They are seeking a Vice President of Oligonucleotide Therapeutics to lead oligonucleotide drug discovery and development programs, driving them from target validation through IND submission.
BiotechnologyManufacturingPharmaceutical
Responsibilities
Program ownership: Serve as program owner for oligonucleotide discovery and development programs, driving them from target validation through DC nomination and IND submission
Oligo design and development: Lead the strategy and execution for antisense oligonucleotides and siRNAs, with a particular emphasis on conjugated oligos (e.g., GalNAc, peptide, antibody, or other ligand-based conjugates)
Assay development: Establish and oversee cellular and biochemical assays to evaluate oligo potency, specificity, uptake, trafficking, and mechanism of action. Ensure assay platforms are robust, scalable, and reproducible
Conjugation biology: Partner closely with chemistry and delivery teams to design and optimize conjugated oligos; directly contribute to design hypotheses and screen conjugates in relevant cellular and in vivo models
Development candidate nomination: Drive scientific packages and cross-functional decision-making to select and nominate oligo development candidates for IND-enabling studies
IND-enabling leadership: Guide IND-enabling biology and translational strategy, integrating preclinical data, biomarkers, and mechanistic insights into regulatory filings
Translational strategy: Build and apply translational models that connect preclinical findings with human biology. Develop and integrate biomarker strategies to guide dose selection, patient stratification, and early clinical readouts
Cross-functional leadership: Lead and inspire cross-functional program teams, ensuring alignment across biology, chemistry, DMPK, CMC, toxicology, and clinical groups to deliver on program objectives
External collaboration: Evaluate and manage CROs and academic partnerships to accelerate program timelines while ensuring scientific rigor and data quality
Regulatory support: Provide biological and translational expertise to regulatory documents, including IND packages, Investigator’s Brochures, and briefing books
Qualification
Required
Accomplished leader in oligonucleotide drug discovery and development
Strong track record of advancing oligonucleotides (conjugated and unconjugated) from concept through development candidate (DC) nomination and into IND
Deep expertise in assay development, oligo design, and translational research
Ability to own programs end-to-end
Hands-on when needed
Excellence in setting scientific vision, leading cross-functional execution, and ensuring rigorous decision-making in a lean, high-impact environment
Serve as program owner for oligonucleotide discovery and development programs
Drive programs from target validation through DC nomination and IND submission
Lead the strategy and execution for antisense oligonucleotides and siRNAs
Establish and oversee cellular and biochemical assays to evaluate oligo potency, specificity, uptake, trafficking, and mechanism of action
Ensure assay platforms are robust, scalable, and reproducible
Partner closely with chemistry and delivery teams to design and optimize conjugated oligos
Drive scientific packages and cross-functional decision-making to select and nominate oligo development candidates for IND-enabling studies
Guide IND-enabling biology and translational strategy
Build and apply translational models that connect preclinical findings with human biology
Develop and integrate biomarker strategies to guide dose selection, patient stratification, and early clinical readouts
Lead and inspire cross-functional program teams
Evaluate and manage CROs and academic partnerships
Provide biological and translational expertise to regulatory documents
Preferred
Ph.D. in molecular biology, pharmacology, or related field, or equivalent advanced degree
12+ years of experience in oligonucleotide drug discovery and development, with at least 5 years in a leadership role
Strong track record of nominating oligonucleotide development candidates and driving programs into IND
Expertise in assay development, in vitro and in vivo pharmacology, and translational/biomarker strategy
Demonstrated ability to lead cross-functional programs through IND-enabling studies
Regulatory-facing experience strongly preferred
Benefits
Robust and market-competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs)
Flexible PTO
Rapid career advancement for strong performers
Potential ability to work on multiple GondolaBio Pharma programs across multiple therapeutic areas over time
Partnerships with leading institutions
Commitment to Diversity, Equity & Inclusion
Company
GondolaBio
GondolaBio researches, develops and manufactures pharmaceutical products. It is a sub-organization of BridgeBio.
11-50 employees
Funding
Current Stage
Early StageTotal Funding
$300M2024-08-16Series Unknown· $300M
Leadership Team
J
James Li
President
Recent News
Company data provided by crunchbase